Course Information

Release date: December 19, 2025
Expiration date: December 19, 2026
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharpe & Dohme LLC.

PROGRAM OVERVIEW

Join leaders in gynecologic oncology, Drs. Monk, Gaillard, Matulonis, and Slomovitz for a 1-hour continuing education course on the management of advanced endometrial cancer (EC). Using “real-world” cases, leaders in the field will connect clinical data to guideline-informed recommendations from biomarker testing to frontline and later-line care. This program will update and confirm your practice with expert insights on adverse event monitoring and management, multidisciplinary care, and strategies to address disparities in care.

Learning Objectives

TARGET AUDIENCE

This activity addresses the needs of medical oncologists, gynecologic oncologists, surgeons, radiation oncologists, pathologists, nurses, and other healthcare professionals involved in the management of patients with EC.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Evaluate molecular testing results and clinical parameters to develop personalized treatment algorithms for patients with EC considering immunotherapy and targeted approaches
Appraise current and emerging clinical trial data to formulate evidence-based decisions about immunotherapy regimens and combinations, accounting for biomarker status, prior therapies, and patient-specific factors
Design coordinated, team-based strategies, selection of treatment, and monitoring immune-related adverse events while recognizing potential barriers to care delivery and developing solutions to address healthcare disparities

Faculty Information and Disclosures

FACULTY CHAIR

Bradley J. Monk, MD, FACS, FACOG

Medical Director, Late-Phase Clinical Research
Florida Cancer Specialists and Research Institute
Winter Park, Florida
Professor, Obstetrics and Gynecology
University of Central Florida College of Medicine
Orlando, Florida

FACULTY PANEL

	Stephanie Galliard, MD, PhD Associate Professor, Department of Oncology Director, Gynecologic Cancer Trials Co-Director, Developmental Therapeutics Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Baltimore, Maryland
	Ursula A. Matulonis, MD Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Professor of Medicine Harvard Medical School Boston, Massachusetts
	Brian Slomovitz, MD Director, Gynecologic Oncology Mount Sinai Medical Center Miami Beach, Florida

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Stephanie Galliard, MD, PhD
Advisory Board: AstraZeneca
Consultant: Organon, Orion
Grant for Clinical Trial (to Institution): AstraZeneca, Beigene/BeOne, Blueprint, GOG Foundation/Clovis/Pharma&, Immunogen, Tempest, Verastem, Volastra
Independent Data Monitoring Committee: TORL BioTherapeutics LLC
Inventor (No Compensation): United States Patent Nos 10,258,604 & 10,905,659, Lasofoxifene treatment of breast cancer, licensed by Duke University to Sermonix
Safety Review Committee Member (No Compensation): SignPath Pharma
Steering Committee Member (No Compensation): Tesaro

Ursula A. Matulonis, MD
Advisory Boards: AbbVie, AstraZeneca, Daiichi Sankyo, Day One, GlaxoSmithKline, Merck, Next Cure, Whitehawk Data Safety Monitoring Committee: AstraZeneca, Macrogenics, Symphogen

Bradley J. Monk, MD, FACS, FACOG
Consultant: AstraZeneca, AbbVie, BioNtech, Corcept, Daiichi Sankyo, Eisai, Eli Lilly, Genmab/Seagen/Pfizer, GlaxoSmithKline, GOG Foundation, Immunogen/AbbVie, Incyte, Karyopharm, Merck, Mersana, Mural/Alkermes, Myriad, Natera, Novartis, Novocure, OncoC4, Panavance, Pharma&, ProfoundBio/Genmab, Regeneron, Roche/Genentech, Sutro, Tubulis, Verastem, Zai Labs, Zentalis, Zymeworks
Speaker: AstraZeneca, Daiichi Sankyo, Eisai, Immunogen/AbbVie, Merck, Takeda, Zai Labs

Brian Slomovitz, MD
Consultant: AstraZeneca, Beigene, Daiichi Sankyo, Eisai, Genmab US, GlaxoSmithKline, Incyte, Karyopharm, Merck Sharp & Dohme

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 19, 2025 through December 19, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will issued by our system and immediately available for download upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you register or participate in an educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and… (continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 19, 2025Expiration date: December 19, 2026Estimated time to complete activity: 60 minutes

Updating Practice in Endometrial Cancer: Integrating Biomarker Assessments, Immunotherapy, and ADC Combinations in a Multidisciplinary Care Paradigm